Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Open accessThe DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.
Abstract
Mood disorders are common, chronic, recurrent mental illnesses that affect the lives of millions of individuals worldwide. To date, the monoaminergic systems (serotonergic, noradrenergic and dopaminergic) in the brain have received the greatest attention in neurobiological studies of mood disorders, and most therapeutics target these systems. However, there is growing evidence that the glutamatergic system is central to the neurobiology and treatment of these disorders. Here, we review data supporting the involvement of the glutamatergic system in mood-disorder pathophysiology as well as the efficacy of glutamatergic agents in mood disorders. We also discuss exciting new prospects for the development of improved therapeutics for these devastating disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This could lead to astrocyte/microglia imbalance, glutamatergic overproduction and excitotoxic neuronal damage (Sanacora et al., 2008) with impact on synapse functionality.”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, increased glutamate levels has been associated with mechanisms involved in stress and depression, such as neuro-inflammatory process, decreased levels of neurotrophic factors, diminished neurogenesis, and neuroplasticity impairment [116,117].”
From P2X7 Receptor Signaling in Stress and Depression (2019) · cites this paper as [117]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, rapidly acting antidepressants were discovered in the glutamatergic system (Berman et al., 2000;Sanacora et al., 2008).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Several classes of antidepressants as well as SSRIs are known to exert action on the glutamate system by influencing NMDA or AMPA receptor transcription (Sanacora et al., 2008).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Glia also play an important role in regulating the synthesis and reuptake of glutamate and thereby influence synaptic function and morphology16,17.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“Although most patients with mood disorders receive some benefit from available treatment”
BackgroundTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationEvidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043 · cited 1×
“, and is approved for the treatment of moderate to severe Alzheimer's disease, in which it has been shown to enhance cognition and minimize clinical deterioration in patients with Alzheimer's disease, vascular dementia or mixed dementi”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Research works printed but not linked: 1
- Preskorn, S. et al. A placebo-controlled trial of the NR2B subunit specific NMDA antagonist CP-101,606 plus paroxetine for treatment resistant depression (TRD). Annual Conference of the American Psychological Association (San Francisco, California) 154 (2007).
Cited by
Items 401–500 of 1,000
Chappell, M. D., Li, R., Smith, S. C., Dressman, B. A., Tromiczak, E. G., Tripp, A. E., Blanco, M.-J., Vetman, T. N., Quimby, S. J., Matt, J. E., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01119 · Cited by 30
Monn, J. A., Henry, S. S., Massey, S. M., Clawson, D. K., Chen, Q., Diseroad, B. A., Bhardwaj, R. M., Atwell, S., Lu, F., Wang, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01481 · Cited by 30
Ueno, H., Shimada, A., Suemitsu, S., Murakami, S., Kitamura, N., Wani, K., Matsumoto, Y., Okamoto, M., & Ishihara, T. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/2745453 · Cited by 30
Benefits of animal models to understand the pathophysiology of depressive disorders
Czéh, B., & Simon, M. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110049 · Cited by 30
Alttoa, A. (2004) · DSpace repository (University of Tartu) · Cited by 30
Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review
Demchenko, I., Tassone, V. K., Kennedy, S. H., Dunlop, K., & Bhat, V. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.864902 · Cited by 29
“Several 1H-MRS studies, on the other hand, have reported increased (51– 53) and unchanged (54, 55) glutamate/GLX levels in MDD participants, suggesting that the direction and magnitude of glutamate-specific alterations may differ depending on the brain region or the network of interest (56).”
BackgroundGuo, F., Zhang, Q., Zhang, B., Fu, Z., Wu, B., Huang, C., & Li, Y. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12725 · Cited by 29
van de Loo, A. J. A. E., Bervoets, A. C., Mooren, L., Bouwmeester, N. H., Garssen, J., Zuiker, R., van Amerongen, G., van Gerven, J., Singh, J., der Ark, P. V., et al. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4706-6 · Cited by 29
Kołtunowska, D., Gibula-Bruzda, E., & Kotlinska, J. H. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.04.013 · Cited by 29
Taylor, M. J., Godlewska, B., Near, J., Christmas, D., Potokar, J., Collier, J., Klenerman, P., Barnes, E., & Cowen, P. J. (2014) · Psychological Medicine · doi:10.1017/s0033291713001062 · Cited by 26
Öngür, D., Haddad, S. A., Prescot, A. P., Jensen, J. E., Siburian, R., Cohen, B. M., Renshaw, P. F., & Smoller, J. W. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.01.033 · Cited by 29
Stan, T. L., Alvarsson, A., Branzell, N., Sousa, V. C., & Svenningsson, P. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.39 · Cited by 29
Xia, B., Zhang, H., Xue, W., Tao, W., Chen, C., Wu, R., Ren, L., Tang, J., Wu, H., Cai, B., et al. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0316-1 · Cited by 29
Chakraborty, S., Tripathi, S. J., Srikumar, B. N., Raju, T. R., & Rao, B. S. S. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104605 · Cited by 29
Şahin, C., Dursun, S. M., Çetin, M., & Arıcıoğlu, F. (2016) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20160520092044 · Cited by 29
Recent advances in psychoneuroimmunology: Inflammation in psychiatric disorders
Debnath, M., Doyle, K., Langan, C., McDonald, C., Leonard, B., & Cannon, D. (2011) · Translational Neuroscience · doi:10.2478/s13380-011-0019-0 · Cited by 28
Early Life Stress Increases Brain Glutamate and Induces Neurobehavioral Manifestations in Rats
Guan, J., Ding, Y., Rong, Y., Geng, Y., Lai, L., Qi, D., Tang, Y., Yang, L., Li, J., Zhou, T., et al. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00454 · Cited by 28
Dysbindin (DTNBP1) – A role in psychotic depression?
Domschke, K., Lawford, B. R., Young, R. M., Voisey, J., Morris, C. P., Roehrs, T., Hohoff, C., Birosova, E., Arolt, V., & Baune, B. T. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.09.014 · Cited by 28
Yuxiang, X., Li, Y., Wang, C., Han, T., Yue, W., Wang, S., & Wei, J. (2024) · International Journal of Clinical and Health Psychology · doi:10.1016/j.ijchp.2023.100433 · Cited by 28
Francotte, P., Nørholm, A., Deva, T., Olsen, L., Frydenvang, K., Goffin, E., Fraikin, P., Tullio, P. D., Challal, S., Thomas, J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501268r · Cited by 28
Das, P., Tanious, M., Fritz, K., Dodd, S., Dean, O. M., Berk, M., & Malhi, G. S. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412474074 · Cited by 28
Čolić, L., von Düring, F., Denzel, D., Demenescu, L. R., Lord, A., Martens, L., Lison, S., Frommer, J., Vogel, M., Kaufmann, J., et al. (2019) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2019.04.003 · Cited by 28
Glutamate-Mediated Neuroplasticity Deficits in Mood Disorders
Reznikov, L. R., Fadel, J. R., & Reagan, L. P. (2011) · doi:10.1007/978-1-908517-18-0_2 · Cited by 28
Rapid Antidepressant Response with Ketamine: Is it the Solution to Resistant Depression?
Thakurta, R. G., Ray, P., Kanji, D., Das, R., Bisui, B., & Singh, O. P. (2012) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.96161 · Cited by 28
Réus, G. Z., Nacif, M., Abelaira, H. M., Tomaz, D. B., Santos, M. A., Carlessi, A. S., Matias, B. I., da Luz, J. R., Steckert, A. V., Jeremias, G. C., et al. (2015) · Current Neurovascular Research · doi:10.2174/1567202612666150122122924 · Cited by 28
Fumagalli, F., Pasini, M., Sartorius, A., Scherer, R., Racagni, G., Riva, M. A., & Gass, P. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000544 · Cited by 28
Wang, X., Zhang, F., Niu, L., Yan, J., Liu, H., Wang, D., Hui, J., Dai, H., Song, J., & Zhang, Z. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.12.068 · Cited by 27
Pain and the Brain: Diabetic Neuropathic Pain
Jain, R. K. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0808e22 · Cited by 27
4-Aryl piperazine and piperidine amides as novel mGluR5 positive allosteric modulators
Xiong, H., Brugel, T. A., Balestra, M., Brown, D. G., Brush, K. A., Hightower, C., Hinkley, L., Hoesch, V., Kang, J. J., Koether, G. M., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.10.036 · Cited by 27
Zhang, Y., Xu, Z., Zhang, S., Desrosiers, A., Schottenfeld, R. S., & Chawarski, M. C. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.02.010 · Cited by 27
dos Santos, K. C., Borges, T. V., Olescowicz, G., Ludka, F. K., Santos, C. A. D. M., & Molz, S. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12512 · Cited by 27
Deletion of serine racemase confers D-serine –dependent resilience to chronic social defeat stress
Dong, C., Zhang, J., Ren, Q., Ma, M., Qu, Y., Zhang, K., Yao, W., Ishima, T., Mori, H., & Hashimoto, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.03.008 · Cited by 27
The Role of miR-150 in Stress-Induced Anxiety-Like Behavior in Mice
Zhang, W., Cao, W.-Y., Huang, Y., Cui, Y., Tu, B.-X., Wang, L.-F., Zou, G.-J., Liu, Y., Hu, Z., Hu, R., et al. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9943-x · Cited by 27
Zhao, A., Ma, B., Xu, L., Yao, M., Zhang, Y., Xue, B., Ren, J., Chang, D., & Liu, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.662003 · Cited by 27
Luttenbacher, I., Phillips, A., Kazemi, R., Hadipour, A. L., Sanghvi, I., Martínez-Agosto, J. A., & Adamson, M. M. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.12.042 · Cited by 27
Ketamine as a rapid antidepressant: the debate and implications
Ho, R. C. M., & Zhang, M. W. (2016) · BJPsych Advances · doi:10.1192/apt.bp.114.014274 · Cited by 24
Predictive coding in neuropsychiatric disorders: a systematic transdiagnostic review.
Qela, B., Damiani, S., De Santis, S., Groppi, F., Pichiecchio, A., Asteggiano, C., Brondino, N., Monteleone, A. M., Grassi, L., Politi, P., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106020 · Cited by 26
“…mood disorders are typically managed with medications acting on the monoaminergic and glutamatergic systems, both playing a critical role in mood, behavioral, and cognitive regulation, including predictive performance (Gilbert et al., 2022; Goulty et al., 2023; Pal, 2021; Sanacora et al., 2008).”
Cytokines and depression: findings, issues, and treatment implications
Sharpley, C. F., & Agnew, L. L. (2011) · revneuro · doi:10.1515/rns.2011.030 · Cited by 26
Frank, D., Gruenbaum, B., Shelef, I., Zvenigorodsky, V., Severynovska, O., Fleidervish, I., Knyazer, B., Frenkel, A., Zlotnik, A., Kofman, O., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02329-1 · Cited by 24
Rosenthal-Simons, A., Durrant, A. R., & Heresco‐Levy, U. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.05.008 · Cited by 26
Oliva, J. L., Leung, S., Croft, R. J., O’Neill, B. V., O'Kane, J., Stout, J. C., Phan, K. L., & Nathan, P. J. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1133 · Cited by 26
Rathje, M., Waxman, H., Benoit, M., Tammineni, P., Leu, C., Loebrich, S., & Nedivi, E. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0314-z · Cited by 26
Goldschmied, J., & Gehrman, P. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1013-4 · Cited by 26
Zhu, L., Shi, H., Chang, L., Zhang, C. C., Si, M., Li, N., & Zhu, D. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15084 · Cited by 26
Perisynaptic astrocytes as a potential target for novel antidepressant drugs
Frizzo, M. E., & Ohno, Y. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.11.002 · Cited by 26
Wang, Y., Ma, Y., Cheng, W., Jiang, H., Zhang, X., Li, M., Ren, J., Zhang, X., & Li, X. (2015) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2015.01.003 · Cited by 26
Human nasal olfactory epithelium as a dynamic marker for CNS therapy development
Sattler, R., Ayukawa, Y., Coddington, L. T., Sawa, A., Block, D., Chipkin, R. E., & Rothstein, J. D. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.09.002 · Cited by 25
Stoker, A. D., Rosenfeld, D. M., Buras, M. R., Alvord, J. M., & Gorlin, A. W. (2019) · Journal of Pain Research · doi:10.2147/jpr.s217005 · Cited by 25
Neuroendocrine and Neurochemical Processes in Depression
Cowen, P. J. (2015) · Psychopathology Review · doi:10.5127/pr.034513 · Cited by 25
Therapeutic Implications of microRNAs in Depressive Disorders: A Review
Hassan, M., Amir, A., Shahzadi, S., & Kloczkowski, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113530 · Cited by 24
Peng, L., Li, B., Du, T., Wang, F., & Hertz, L. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.021 · Cited by 24
Deng, L., Shi, A., & Wang, Q. (2018) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.9020 · Cited by 24
Altinay, M. I., Karne, H. S., & Anand, A. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4588 · Cited by 24
Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01086-1 · Cited by 24
Pignatelli, M., Vollmayr, B., Richter, S. H., Middei, S., Matrisciano, F., Molinaro, G., Nasca, C., Battaglia, G., Ammassari‐Teule, M., Feligioni, M., et al. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.046 · Cited by 24
Poletti, S., Locatelli, C., Falini, A., Colombo, C., & Benedetti, F. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.07.007 · Cited by 24
Botanas, C. J., de la Peña, J. B., Custodio, R. J. P., Peña, I. J. D., Kim, M., Woo, T., Kim, H. J., Kim, H. I., Cho, M. C., Lee, Y. S., et al. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.038 · Cited by 24
Wirgenes, K. V., Djurovic, S., Agartz, I., Jönsson, E. G., Werge, T. M., Melle, I. S., & Andreassen, O. A. (2009) · Neuropsychobiology · doi:10.1159/000235799 · Cited by 24
Kato, M., Ogata, H., Tahara, H., Shimamoto, A., Takekita, Y., Koshikawa, Y., Nishida, K., Nonen, S., Higasa, K., & Kinoshita, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073873 · Cited by 23
Salvadore, G., & Zarate, C. A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.011 · Cited by 23
Self-citationAlterations of the glutamatergic system in diabetes mellitus
Hristov, M., Nankova, A., & Andreeva-Gateva, P. A. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01299-z · Cited by 23
Behavioral Neurobiology of Bipolar Disorder and its Treatment
Manji, H. K., & Zarate, C. A. (2010) · Current topics in behavioral neurosciences · doi:10.1007/978-3-642-15757-8 · Cited by 23
Self-citationLithgow, B., Moussavi, Z., & Fitzgerald, P. B. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1599143 · Cited by 23
Kühn, M., Maier, J. G., Wolf, E., Mainberger, F., Feige, B., Maywald, S., Bredl, A., Michel, M., Sendelbach, N., Normann, C., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.08.052 · Cited by 23
Watanabe, M., Marcy, B., Hiroki, A., Watase, H., Kinoshita, K., Iijima, M., Marumo, T., Zarate, C. A., & Chaki, S. (2022) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab062 · Cited by 22
Self-citationMarszalek-Grabska, M., Gibula-Bruzda, E., Jenda, M., Gawel, K., & Kotlinska, J. H. (2016) · Brain Research · doi:10.1016/j.brainres.2016.04.026 · Cited by 22
Dyomina, A. V., Kovalenko, A. A., Zakharova, M. V., Postnikova, T. Y., Griflyuk, A. V., Smolensky, I. V., Antonova, I., & Zaitsev, A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010497 · Cited by 22
The neurobiological mechanisms and therapeutic prospect of extracellular ATP in depression
Wang, K., Huang, S., Fu, D., Yang, X., Ma, L., Zhang, T., Zhao, W., Deng, D., Ding, Y., Zhang, Y., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14536 · Cited by 22
Mueller, R. W., Rachwał, S., Lee, S. S., Zhong, S., Li, Y.-X., Haroldsen, P. E., Herbst, T., Tanimura, S. M., Varney, M. A., Johnson, S., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.07.098 · Cited by 22
Monn, J. A., Valli, M. J., Massey, S. M., Hao, J., Reinhard, M. R., Bures, M. G., Heinz, B. A., Wang, X.-S., Carter, J. H., Getman, B. G., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4000165 · Cited by 22
The Role of NMDA Receptors in the Development of Brain Resistance through Pre- and Postconditioning
Constantino, L. C. (2014) · Aging and Disease · doi:10.14336/ad.2014.0500430 · Cited by 22
Besckow, E. M., Nonemacher, N. T., Garcia, C. S., Espíndola, C. N. D. S., Balbom, É. B., Gritzenco, F., Savegnago, L., Godoi, B., Bortolatto, C. F., & Brüning, C. A. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05600-1 · Cited by 22
Effect of age on brain metabotropic glutamate receptor subtype 5 measured with [18F]FPEB PET
Mecca, A. P., Rogers, K., Jacobs, Z., McDonald, J. W., Michalak, H. R., DellaGioia, N., Zhao, W., Hillmer, A. T., Nabulsi, N., Lim, K., et al. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118217 · Cited by 22
Rogóż, Z., Kamińska, K., Lech, M. A., & Lorenc‐Koci, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042125 · Cited by 22
Vasiliu, O. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.884155 · Cited by 22
Studies of Depression-Related States in Animal Models of Parkinsonism
Schintu, N., Zhang, X., & Svenningsson, P. (2012) · Journal of Parkinson s Disease · doi:10.3233/jpd-2012-12076 · Cited by 22
Plasma Amino Acid Levels Discriminate Between Control Subjects and Mildly Depressed Elderly Women
Mayoral-Mariles, A., Cruz-Revilla, C., Vega-Manríquez, X., Aguirre‐Hernández, R., Severiano‐Pérez, P., Aburto-Arciniega, E., Mendoza, A. J., & Guevara‐Guzmán, R. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.07.006 · Cited by 22
The Ampa Receptor as a Therapeutic Target: Current Perspectives and Emerging Possibilities
Mellor, I. R. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.27 · Cited by 22
Inflammation Effects on Glutamate as a Pathway to Neuroprogression in Mood Disorders
Haroon, E., & Miller, A. H. (2017) · Modern trends in psychiatry · doi:10.1159/000470805 · Cited by 22
Antidepressant effect of vagal nerve stimulation in epilepsy patients: a systematic review
Assenza, G., Tombini, M., Lanzone, J., Ricci, L., Lazzaro, V. D., Casciato, S., Morano, A., Giallonardo, A. T., Bonaventura, C. D., Beghi, E., et al. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04479-2 · Cited by 22
Pringle, A., Parsons, E., Cowen, L., McTavish, S., Cowen, P., & Harmer, C. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112446535 · Cited by 21
Clinical overview of NMDA-R antagonists and clinical practice
Davoudian, P. A., & Wilkinson, S. T. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.04.004 · Cited by 21
Madjid, N., Lidell, V., Nordvall, G., Lindskog, M., Ögren, S.-O., Forsell, P., & Sandin, J. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06410-x · Cited by 19
Su, Z., Zhang, H., Wang, Y., Chen, B., Zhang, Z., Wang, B., Liu, J., Shi, Y., & Zhao, X. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1424666 · Cited by 21
Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders
Costi, S., Dam, N. T. V., & Murrough, J. W. (2015) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-015-0052-3 · Cited by 21
Pennybaker, S. J., Roach, B. J., Fryer, S. L., Badathala, A., Wallace, A., Mathalon, D. H., & Marton, T. F. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05939-z · Cited by 21
Irvine, M. W., Costa, B. M., Dlaboga, D., Culley, G. R., Hulse, R. P., Scholefield, C. L., Atlason, P. T., Fang, G., Eaves, R. J., Morley, R., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201230z · Cited by 21
Taylor, M., Norbury, R., Murphy, S. E., Rudebeck, S. R., Jezzard, P., & Cowen, P. J. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109105679 · Cited by 21
Stevens, J., Bies, R. R., Shekhar, A., & Anand, A. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04398.x · Cited by 21
Wang, Y., Ma, Y., Hu, J., Zhang, X., Cheng, W., Jiang, H., Li, M., Ren, J., Zhang, X., Liu, M., et al. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.04.016 · Cited by 21
Possible antidepressant mechanism of acupuncture: targeting neuroplasticity
Xu, N., He, Y., Wei, Y.-N., Bai, L., & Wang, L. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1512073 · Cited by 20
Neurobiological Mechanisms of Electroconvulsive Therapy: Molecular Perspectives of Brain Stimulation
Fetahović, E., Janjic, V. S., Muric, M. D., Jovicic, N. U., Radmanović, B., Rosic, G. L., Selaković, D., Filipovic, M., & Muric, N. N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125905 · Cited by 20
Tillmann, S., Pereira, V. S., Liebenberg, N., Christensen, A. K., & Wegener, G. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182698 · Cited by 20
Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression
Fagerholm, E. D., Leech, R., Williams, S., Zarate, C. A., Moran, R., & Gilbert, J. R. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01442-3 · Cited by 20
Self-citationKim, J., An, B., Kim, J., Park, S., Park, S., Hong, I., Lee, S., Park, K., & Choi, S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.145 · Cited by 20
Riluzole effect on occipital cortex: A structural and spectroscopy pilot study
Abdallah, C. G., Coplan, J. D., Jackowski, A. P., Sato, J. R., Mao, X., Shungu, D. C., & Mathew, S. J. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.09.054 · Cited by 20
Ai, H., Shi, X., Hu, X., Fang, W., Zhang, B., & Lu, W. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.03.029 · Cited by 20
Pilar-Cuéllar, F., Castro, E., Bretin, S., Mocaër, E., Pazos, Á., & Díaz, Á. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.04.005 · Cited by 20
Efficacy of Ketamine in bipolar depression: focus on anhedonia.
Gałuszko‐Węgielnik, M., Wiglusz, M. S., Słupski, J., Szałach, Ł. P., Włodarczk, A., Górska, N., Szarmach, J., Jakuszkowiak‐Wojten, K., Wilkowska, A., & Cubała, W. J. (2019) · PubMed · Cited by 20
Liao, W.-T., Tseng, C.-C. A., Chia, W.-T., & Lin, C. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.09.005 · Cited by 20
Metadata
- Authors
- Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K.
- Affiliations
- Yale University (US)
- National Institutes of Health (US)
- Corresponding author
- Manji, Husseini K.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2008-05
- Volume
- 7
- Issue
- 5
- Pages
- 426-437
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC2715836
- OpenAlex
- W2074907255
- Cited by
- 894
- References
- 186
- Citations by year
- 2026: 17 · 2025: 29 · 2024: 33 · 2023: 44 · 2022: 36 · 2021: 44 · 2020: 56 · 2019: 43 · 2018: 40 · 2017: 50 · 2016: 63 · 2015: 70 · 2014: 59 · 2013: 56 · 2012: 68
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (K02MH076222, Z01MH002828, Z01MH002857)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- glutamatergic system, mood disorders, antidepressants, neuroplasticity, glutamatergic agents, monoaminergic systems, rapid-acting antidepressants, drug development
- MeSH terms
- Animals, Glutamates, Humans, Psychotropic Drugs, Excitatory Amino Acid Antagonists, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.